BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 11237284)

  • 1. Pathogenesis of thyroid nodules: histological classification?
    Salabè GB
    Biomed Pharmacother; 2001 Feb; 55(1):39-53. PubMed ID: 11237284
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of the hepatocyte growth factor and c-met in normal thyroid, non-neoplastic, and neoplastic nodules.
    Trovato M; Villari D; Bartolone L; Spinella S; Simone A; Violi MA; Trimarchi F; Batolo D; Benvenga S
    Thyroid; 1998 Feb; 8(2):125-31. PubMed ID: 9510120
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection of RET/PTC, TRK and BRAF mutations in preoperative diagnosis of thyroid nodules with indeterminate cytological findings.
    Sapio MR; Posca D; Raggioli A; Guerra A; Marotta V; Deandrea M; Motta M; Limone PP; Troncone G; Caleo A; Rossi G; Fenzi G; Vitale M
    Clin Endocrinol (Oxf); 2007 May; 66(5):678-83. PubMed ID: 17381488
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinicopathological correlation of serum TSH in patients with thyroid nodule.
    Mondal HP; Sen S; Sasmal S; Ghosal PK; Mukhopadhyay SK; Mukhopadhyay M
    J Indian Med Assoc; 2011 May; 109(5):330, 335, 338. PubMed ID: 22187768
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HGF/C-MET system pathways in benign and malignant histotypes of thyroid nodules: an immunohistochemical characterization.
    Ruggeri RM; Vitarelli E; Barresi G; Trimarchi F; Benvenga S; Trovato M
    Histol Histopathol; 2012 Jan; 27(1):113-21. PubMed ID: 22127603
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of RET/PTC oncogene activation and clonality in thyroid nodules with incomplete morphological evidence of papillary carcinoma: a search for the early precursors of papillary cancer.
    Fusco A; Chiappetta G; Hui P; Garcia-Rostan G; Golden L; Kinder BK; Dillon DA; Giuliano A; Cirafici AM; Santoro M; Rosai J; Tallini G
    Am J Pathol; 2002 Jun; 160(6):2157-67. PubMed ID: 12057919
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Focal Lymphocytic Thyroiditis Nodules Share the Features of Papillary Thyroid Cancer on Ultrasound.
    Hwang S; Shin DY; Kim EK; Yang WI; Byun JW; Lee SJ; Kim G; Im SJ; Lee EJ
    Yonsei Med J; 2015 Sep; 56(5):1338-44. PubMed ID: 26256977
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Functioning and nonfunctioning thyroid adenomas involve different molecular pathogenetic mechanisms.
    Tonacchera M; Vitti P; Agretti P; Ceccarini G; Perri A; Cavaliere R; Mazzi B; Naccarato AG; Viacava P; Miccoli P; Pinchera A; Chiovato L
    J Clin Endocrinol Metab; 1999 Nov; 84(11):4155-8. PubMed ID: 10566665
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Solitary thyroid nodule: a study of 100 cases.
    Das AB; Alam MN; Haq SA; Ansari MA; Rahman AN; Hasan M; Yasmeen S; Haque MM; Tahir M; Karim MA
    Bangladesh Med Res Counc Bull; 1996 Apr; 22(1):12-8. PubMed ID: 9037840
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular aspects of the pathogenesis of nodular goiters, thyroid nodules and adenomas.
    Derwahl M
    Exp Clin Endocrinol Diabetes; 1996; 104 Suppl 4():32-5. PubMed ID: 8980997
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RET/PTC rearrangements in thyroid nodules: studies in irradiated and not irradiated, malignant and benign thyroid lesions in children and adults.
    Elisei R; Romei C; Vorontsova T; Cosci B; Veremeychik V; Kuchinskaya E; Basolo F; Demidchik EP; Miccoli P; Pinchera A; Pacini F
    J Clin Endocrinol Metab; 2001 Jul; 86(7):3211-6. PubMed ID: 11443191
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Classification of the thyroid nodules based on characteristic sonographic textural feature and correlated histopathology using hierarchical support vector machines.
    Chen SJ; Chang CY; Chang KY; Tzeng JE; Chen YT; Lin CW; Hsu WC; Wei CK
    Ultrasound Med Biol; 2010 Dec; 36(12):2018-26. PubMed ID: 21092831
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hyperfunctioning thyroid nodules in toxic multinodular goiter share activating thyrotropin receptor mutations with solitary toxic adenoma.
    Tonacchera M; Chiovato L; Pinchera A; Agretti P; Fiore E; Cetani F; Rocchi R; Viacava P; Miccoli P; Vitti P
    J Clin Endocrinol Metab; 1998 Feb; 83(2):492-8. PubMed ID: 9467563
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The RET proto-oncogene in medullary and papillary thyroid carcinoma. Molecular features, pathophysiology and clinical implications.
    Komminoth P
    Virchows Arch; 1997 Jul; 431(1):1-9. PubMed ID: 9247627
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Centralized molecular testing for oncogenic gene mutations complements the local cytopathologic diagnosis of thyroid nodules.
    Beaudenon-Huibregtse S; Alexander EK; Guttler RB; Hershman JM; Babu V; Blevins TC; Moore P; Andruss B; Labourier E
    Thyroid; 2014 Oct; 24(10):1479-87. PubMed ID: 24811481
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence and phenotypic correlations of EIF1AX mutations in thyroid nodules.
    Karunamurthy A; Panebianco F; J Hsiao S; Vorhauer J; Nikiforova MN; Chiosea S; Nikiforov YE
    Endocr Relat Cancer; 2016 Apr; 23(4):295-301. PubMed ID: 26911375
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular pathogenesis of thyroid nodules and cancer.
    Moretti F; Nanni S; Pontecorvi A
    Baillieres Best Pract Res Clin Endocrinol Metab; 2000 Dec; 14(4):517-39. PubMed ID: 11289733
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular Testing for Oncogenic Gene Alterations in Pediatric Thyroid Lesions.
    Mostoufi-Moab S; Labourier E; Sullivan L; LiVolsi V; Li Y; Xiao R; Beaudenon-Huibregtse S; Kazahaya K; Adzick NS; Baloch Z; Bauer AJ
    Thyroid; 2018 Jan; 28(1):60-67. PubMed ID: 29108474
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Genetic factors predisposing to the development of papillary thyroid cancer].
    Puzianowska-Kuźnicka M; Pietrzak M
    Endokrynol Pol; 2005; 56(3):339-45. PubMed ID: 16350729
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thyroid nodules with KRAS mutations are different from nodules with NRAS and HRAS mutations with regard to cytopathologic and histopathologic outcome characteristics.
    Radkay LA; Chiosea SI; Seethala RR; Hodak SP; LeBeau SO; Yip L; McCoy KL; Carty SE; Schoedel KE; Nikiforova MN; Nikiforov YE; Ohori NP
    Cancer Cytopathol; 2014 Dec; 122(12):873-82. PubMed ID: 25132659
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.